These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 6622889)

  • 21. Relative antigenicity in mice of H1N1, H3N2 and B strains present in inactivated influenza virus vaccines.
    Profeta ML; Ruggeri M
    Eur J Epidemiol; 1987 Mar; 3(1):61-6. PubMed ID: 3582601
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Responses of elderly and chronically ill subjects to bivalent influenza A/New Jersey/8/76 (Hsw1N1)-A/Victoria/3/75 (H3N2) vaccines.
    Douglas RG; Bentley DW; Brandriss MW
    J Infect Dis; 1977 Dec; 136 Suppl():S526-32. PubMed ID: 342625
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reactogenicity and immunogenicity of whole and ether-Tween-split influenza A virus vaccines in volunteers.
    Jennings R; Clark A; Oxford JS; Hockley DJ; Potter CW
    J Infect Dis; 1978 Nov; 138(5):577-86. PubMed ID: 712115
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant baculovirus influenza A hemagglutinin vaccines are well tolerated and immunogenic in healthy adults.
    Lakey DL; Treanor JJ; Betts RF; Smith GE; Thompson J; Sannella E; Reed G; Wilkinson BE; Wright PF
    J Infect Dis; 1996 Oct; 174(4):838-41. PubMed ID: 8843225
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and immunogenicity of a live-attenuated influenza vaccine blended and filled at two manufacturing facilities.
    Nolan T; Lee MS; Cordova JM; Cho I; Walker RE; August MJ; Larson S; Coelingh KL; Mendelman PM
    Vaccine; 2003 Mar; 21(11-12):1224-31. PubMed ID: 12559802
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin.
    Smith LR; Wloch MK; Ye M; Reyes LR; Boutsaboualoy S; Dunne CE; Chaplin JA; Rusalov D; Rolland AP; Fisher CL; Al-Ibrahim MS; Kabongo ML; Steigbigel R; Belshe RB; Kitt ER; Chu AH; Moss RB
    Vaccine; 2010 Mar; 28(13):2565-72. PubMed ID: 20117262
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum antibody responses after intradermal vaccination against influenza.
    Belshe RB; Newman FK; Cannon J; Duane C; Treanor J; Van Hoecke C; Howe BJ; Dubin G
    N Engl J Med; 2004 Nov; 351(22):2286-94. PubMed ID: 15525713
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A/USSR and B/Hong Kong vaccine. Field experiences during an A/Brazil and an influenza B epidemic.
    Foy HM; Allan I; Blumhagen JM; Cooney MK; Hall C; Fox JP
    JAMA; 1981 May; 245(17):1736-40. PubMed ID: 6163876
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reactogenicity and immunogenicity of parenteral monovalent influenza A/Victoria/3/75 (H3N2) virus vaccine in healthy adults.
    Caplan ES; Hughes TP; O'Donnel S; Levine MM; Hornick RB
    J Infect Dis; 1977 Dec; 136 Suppl():S484-90. PubMed ID: 342622
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of trivalent cold-adapted recombinant (CR) influenza virus vaccine with monovalent CR vaccines in healthy unselected adults.
    Atmar RL; Keitel WA; Cate TR; Quarles JM; Couch RB
    J Infect Dis; 1995 Jul; 172(1):253-7. PubMed ID: 7797925
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High doses of purified influenza A virus hemagglutinin significantly augment serum and nasal secretion antibody responses in healthy young adults.
    Keitel WA; Couch RB; Cate TR; Hess KR; Baxter B; Quarles JM; Atmar RL; Six HR
    J Clin Microbiol; 1994 Oct; 32(10):2468-73. PubMed ID: 7814484
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Topical imiquimod before intradermal trivalent influenza vaccine for protection against heterologous non-vaccine and antigenically drifted viruses: a single-centre, double-blind, randomised, controlled phase 2b/3 trial.
    Hung IF; Zhang AJ; To KK; Chan JF; Li P; Wong TL; Zhang R; Chan TC; Chan BC; Wai HH; Chan LW; Fong HP; Hui RK; Kong KL; Leung AC; Ngan AH; Tsang LW; Yeung AP; Yiu GC; Yung W; Lau JY; Chen H; Chan KH; Yuen KY
    Lancet Infect Dis; 2016 Feb; 16(2):209-18. PubMed ID: 26559482
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Live attenuated and inactivated influenza vaccine in school-age children.
    Gruber WC; Taber LH; Glezen WP; Clover RD; Abell TD; Demmler RW; Couch RB
    Am J Dis Child; 1990 May; 144(5):595-600. PubMed ID: 2330929
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
    Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A graded-dose study of inactivated, surface antigen influenza B vaccine in volunteers: reactogenicity, antibody response and protection to challenge virus infection.
    Goodeve A; Potter CW; Clark A; Jennings R; Schild GC; Yetts R
    J Hyg (Lond); 1983 Feb; 90(1):107-15. PubMed ID: 6822725
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults.
    Powers DC; Smith GE; Anderson EL; Kennedy DJ; Hackett CS; Wilkinson BE; Volvovitz F; Belshe RB; Treanor JJ
    J Infect Dis; 1995 Jun; 171(6):1595-9. PubMed ID: 7769297
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical trials of monovalent influenza A/New Jersey/76 virus vaccines in adults: reactogenicity, antibody response, and antibody persistence.
    Cate TR; Couch RB; Kasel JA; Six HR
    J Infect Dis; 1977 Dec; 136 Suppl():S450-5. PubMed ID: 342620
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The evaluation of the reactogenicity and immunological activity of an inactivated 3-component influenza vaccine with an elevated hemagglutinin concentration in the inoculation dosage].
    Marinich IG; Shadrin AS; Naĭkhin AN; Ivannikov IuG; Kuznetsov NP; Karogodina VI; Shcherbinskaia AM; Voronina EG; Stepankovskaia LD; Eliseeva IV
    Zh Mikrobiol Epidemiol Immunobiol; 1991 Jul; (7):58-61. PubMed ID: 1950267
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibody response to influenza A/New Jersey and A/Victoria virus vaccines in 1976 and subsequent antibody levels after influenza A epidemics, 1977-1979.
    Foy HM; Cooney MK; Taylor J; Allan I; Chuang TY; Blumhagen J; Fox JP
    J Infect Dis; 1980 Aug; 142(2):139-44. PubMed ID: 7410896
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intradermal administration of bivalent and monovalent influenza vaccines.
    Brooks JH; Criep LH; Ruben FL
    Ann Allergy; 1977 Aug; 39(2):110-2. PubMed ID: 889154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.